trustfinance-logo

TrustFinance

  • new

  • Blog

US

    • Voting
    • Awards
    • Rewardsnew
  • industry
    • Regulations
    • Comparison
  • Blog
    • About Us
    • Testimonial
    • Legal
    • Why TrustFinance
    • How TrustFinance works
    • Report
Forex
Crypto
Stock
Financial
Media
Technology
TrustFinance logo

TrustFinance

The most trusted platform

Office: 63 Chulia Street, OCBC Centre East, #15-01, Singapore, 049514
Main contacts:
[email protected]-Technical supports and inquiries
[email protected]-Free online reputation consulting services
[email protected]-Sales inquiries
Business Hours: Mon. - Fri. (11.00-19.00)
Time zone (Singapore)

Features

  • Home
  • Voting
  • Awards
  • Rewardsnew
  • Blog
  • Regulations
  • Comparison

Industry

  • Crypto
  • Financial
  • Forex
  • Media
  • Stock
  • Technology

For Business

  • Business Home
  • Request Demo
  • Solutions
  • Plans & Pricing
  • Events

Our Company

  • About Us
  • Testimonial
  • How TrustFinance Works
  • Why TrustFinance
  • Legal
  • Report
  • Sitemap
DMCA.com Protection Status
Copyright © TrustFinance 2022 | V.2.0

TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

Features
  • Home
  • Voting
  • Awards
  • Rewardsnew
  • Blog
  • Regulations
  • Comparison
Industry
  • Crypto
  • Financial
  • Forex
  • Media
  • Stock
  • Technology
For Business
  • Business Home
  • Request Demo
  • Solutions
  • Plans & Pricing
  • Events
Our Company
  • About Us
  • Testimonial
  • How TrustFinance Works
  • Why TrustFinance
  • Legal
  • Report
  • Sitemap

Community

Office: 63 Chulia Street, OCBC Centre East, #15-01, Singapore, 049514
Main contacts:
[email protected]-Technical supports and inquiries
[email protected]-Free online reputation consulting services
[email protected]-Sales inquiries
Business Hours: Mon. - Fri. (11.00-19.00)
Time zone (Singapore)
DMCA.com Protection Status
Copyright © TrustFinance 2022 | V.2.0

TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

Home
navigate next

Blog

navigate next

Trends

navigate next

EyePoint Sues Ocular Over False Drug Claims

EyePoint Sues Ocular Over False Drug Claims

User profile image

TrustFinance Global Insights

มี.ค. 20, 2026

2 min read

54

EyePoint Sues Ocular Over False Drug Claims

Lawsuit Alleges Misleading Statements

EyePoint Pharmaceuticals has initiated legal action against rival Ocular Therapeutix, filing a lawsuit that accuses the company of disseminating false or misleading information. The complaint centers on EyePoint's lead experimental eye drug, Duravyu.

The lawsuit was officially filed in the Middlesex County Superior Court for the Commonwealth of Massachusetts.

Overview of the Situation

Both companies are significant competitors in the race to develop advanced, longer-lasting treatments for severe retinal diseases. A primary focus is wet age-related macular degeneration, or wet AMD, a leading cause of vision loss among older adults.

EyePoint alleges that Ocular Therapeutix made statements that misrepresented both the company and the clinical results of Duravyu, accusing them of defamation, commercial disparagement, and violations of Massachusetts consumer protection law.

Impact on the Market

EyePoint is seeking a court order to halt the statements, a public retraction, and monetary damages. This legal conflict could influence investor perception and stock performance for both firms as they navigate late-stage trials.

An Ocular spokesperson stated, “We’re confident in our statements and look forward to responding in the course of the legal process.”

Summary

This lawsuit underscores the intense competition within the biopharmaceutical sector, specifically in the ophthalmic drug market. The outcome will be closely monitored by investors, as it could affect the market positions of EyePoint's Duravyu and Ocular's competing drug, Axpaxli.

FAQ

Q: Why is EyePoint suing Ocular Therapeutix?
A: EyePoint alleges that Ocular Therapeutix spread false or misleading information about its company and its experimental eye drug, Duravyu.

Q: What market are these companies competing in?
A: They are competitors in developing treatments for serious retinal diseases, including wet age-related macular degeneration (wet AMD).

Source: Investing.com

Written by

User profile image

TrustFinance Global Insights

AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.

Tags:


Best pick of the Week


Best pick of the Week


Related Articles

LOGO_05_98b94748e3_wYnrSPIJna.png

18 พ.ค. 2026

Goldman Sachs Sets $5,400 Gold Target on Central Bank Demand

LOGO_05_98b94748e3_wYnrSPIJna.png

18 พ.ค. 2026

China Commits to 17 Billion Annual Surge in US Farm Imports

LOGO_05_98b94748e3_wYnrSPIJna.png

18 พ.ค. 2026

Goldman Sachs Warns Energy Shock Could Boost US Dollar

edited

18 พ.ค. 2026

Asian Stocks Slip Amid Tech Losses, Mideast Tensions

edited

18 พ.ค. 2026

Hancock Prospecting Adds Defence Stocks to US Portfolio

edited

18 พ.ค. 2026

Trump Proposes White House Helipad for South Lawn

edited

18 พ.ค. 2026

Asian FX Weakens on Iran Tensions, Soft China Data

edited

18 พ.ค. 2026

Samsung Stock Jumps as SKorea Averts Chip Strike

Transforming CX into Business Growth – Get Your Free White Paper

Top 10 Cryptocurrencies Worth Investing in 2024-2025 Latest Update

Selecting a Gold Trading Broker: An In-Depth Analysis of News Trading Strategies

Evaluating Alternatives to Proprietary Trading Assessments: Leveraging Strategic Bonuses for Private Portfolio Management

The 5 Levels of Forex Broker License

Transforming CX into Business Growth – Get Your Free White Paper

Top 10 Cryptocurrencies Worth Investing in 2024-2025 Latest Update

Selecting a Gold Trading Broker: An In-Depth Analysis of News Trading Strategies

Evaluating Alternatives to Proprietary Trading Assessments: Leveraging Strategic Bonuses for Private Portfolio Management

The 5 Levels of Forex Broker License